Table of Contents

MASH is a growing health problem in the US, affecting about 1 in 20 people. In its early stages, it often causes no symptoms or only vague ones, which means diagnosis can be delayed. If not treated, MASH can progress to serious complications like cirrhosis, liver cancer, or even the need for a liver transplant. Globally, about 1 in 3 people with overweight or obesity also have MASH.

For years, patients were told that diet and exercise were the only options. Now, Wegovy injection pens have become the first and only GLP-1 receptor agonist (GLP-1 RAs) approved for MASH treatment.

Understand how Wegovy, already famous for weight loss and heart protection, could change the future of liver disease.

Key Takeaways

  • FDA approved Wegovy for MASH with F2-F3 fibrosis in August 2025.
  • Clinical trial data showed strong improvements in liver inflammation and fibrosis.
  • The dosing is the same as in obesity treatment, and the side effect profile is consistent with other GLP-1 drugs.
  • Insurance coverage is more likely than for obesity alone, but usually requires documentation.
  • Wegovy now joins Rezdiffra as one of only two approved MASH therapies.

What Is MASH?

Cropped shot of woman holding paper crafted liver in hands on blue background

MASH (formerly called NASH) is a severe stage of fatty liver disease caused by fat buildup and inflammation in the liver. Over time, it can lead to fibrosis (scarring), cirrhosis, liver cancer, or the need for transplant.

Until 2023, the condition was known as NASH (non-alcoholic steatohepatitis). Experts updated the name to MASH (metabolic dysfunction-associated steatohepatitis) to better reflect its link to obesity, type 2 diabetes, and other metabolic risk factors.

Over the past 20 years, liver cancer caused by MASH has nearly doubled worldwide, making it one of the fastest-growing causes. Unlike viral hepatitis-related cancers, which are declining thanks to vaccines and antivirals, MASH is still rising because it is tied to the global epidemics of obesity and type 2 diabetes.

Wegovy FDA Approval for MASH

On August 15, 2025, the FDA granted accelerated approval for Wegovy (semaglutide) to treat adults with MASH and moderate to advanced fibrosis (stage F2 to F3), but without cirrhosis.

This marks a major step forward in liver care. Until very recently, patients with MASH had no FDA-approved treatment options. Now, Wegovy offers another path alongside lifestyle changes and the first drug approved last year, Rezdiffra.

How Wegovy Works for MASH

Losing weight on its own can do a lot for MASH. Even modest weight loss improves fat buildup (steatosis), inflammation, and sometimes scarring (fibrosis). Since Wegovy is very effective for weight loss and for improving blood sugar control, that’s a big part of why it works.

But researchers think Wegovy may also help the liver in other ways, beyond weight loss alone. Here are the main ideas:

1. Improved insulin response reduces fat flow to the liver

When someone has poor insulin sensitivity (insulin resistance), their fat cells keep breaking down and releasing too many fatty acids into the bloodstream. Those fatty acids then get dumped into the liver, where they pile up, leading to fatty liver and creating toxic byproducts that damage liver cells.

Since Wegovy improves insulin sensitivity, it also slows the breakdown of fat in fat tissue. This means fewer fatty acids are released.

In other words:

    • Without Wegovy: insulin resistance fatty acid spillover fat buildup and damage in the liver
    • With Wegovy: better insulin response less fatty acid spillover less liver fat and less cell stress

2. Healthier fat processing inside the liver

Our liver is the main place where fat is made, and certain processes are involved to regulate how much is burned for energy or stored in fat tissue.

Researchers found that GLP-1 affects fat production in the liver. In their experiment, when GLP-1 levels drop, the liver makes more fat. But when GLP-1 is boosted, it turns on pathways that shut down fat-making genes. This keeps the liver from filling up with fat.

This shift reduces the “fat storage problem” that contributes to MASH.

3. Anti-inflammatory effects inside the liver

In one study, semaglutide lowered signals that normally fuel inflammation in fatty liver. It also switched off an overactive chain reaction in immune cells that drives fat buildup and inflammation.

In addition, the cells cleaned themselves more efficiently (a process called autophagy) and were less likely to die when treated with semaglutide.

Wegovy Clinical Trial Results for MASH

The FDA based its approval on results from the ESSENCE trial, a large, ongoing phase 3 study. At the 72-week biopsy checkpoint, patients on Wegovy saw clear benefits compared to placebo:

Endpoint Wegovy Placebo
MASH resolution without worsening fibrosis 63% 34%
Fibrosis improvement without worsening MASH 37% 22%
Both resolution and fibrosis improvement 33% 16%
Mean change in body weight -10.5% -2.0%

The study will continue for 240 weeks (about 4.5 years) to confirm long-term outcomes like avoiding cirrhosis and liver-related complications.

Wegovy’s Dosing and Side Effects When Used for MASH

When treating non-cirrhotic MASH with moderate to advanced liver fibrosis, Wegovy follows the same 16-week titration schedule used for weight loss.

Treatment Weeks Once Weekly Subcutaneous Dosage
Initiation 1 through 4 0.25 mg
Escalation 5 through 8 0.5 mg
9 through 12 1 mg
13 through 16 1.7 mg
Maintenance 17 and onward

2.4 mg (can be decreased to 1.7 mg if not tolerated)

The side effect pattern seen in MASH treatment is also the same as what’s been reported in Wegovy’s weight-loss trials. The most common are gastrointestinal issues, such as:

    • nausea
    • diarrhea
    • constipation
    • abdominal pain
    • vomiting

These symptoms are generally temporary and tend to improve as your body adjusts to the medication. Doctors also monitor for more serious but less common risks such as pancreatitis and gallbladder problems.

If you’re new to Wegovy, it’s important to know that the drug carries a boxed warning for thyroid C-cell tumors. It should not be used if you or your family have a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2).

Insurance Coverage for Wegovy in MASH

Coverage has always been a challenge for GLP-1 drugs, especially for weight loss. Wegovy’s approval for reducing cardiovascular risk made coverage possible in that group of patients, and the new MASH indication should, in theory, qualify as well.

In practice, though, actual access will depend on each plan’s formulary decisions and the prior authorization requirements they may impose.

  • Medicare Part D: May cover Wegovy for MASH, since this is a recognized medical condition (unlike obesity alone). Medicare Part D often places very expensive drugs like Wegovy in a “specialty tier.” On this tier, instead of paying a flat copay (like $20), patients pay a percentage of the drug’s list price, usually 25% to 33% or about $325-$430 per month out of pocket.
  • Commercial insurance: Some major pharmacy benefit managers (PBMs) have already been preferring Wegovy on some commercial formularies (pre-MASH approval), which suggests coverage could expand further as plans adjust to include the new indication.

If you’re considering it, here are the next steps you should take:

  • Check coverage: Ask your plan about Wegovy for MASH specifically and what documentation they require (biopsy stage, prior auth forms, etc.).
  • Confirm eligibility: Biopsy-proven (or recent) F2-F3 MASH and no cirrhosis.
  • Discuss safety: Screen for thyroid cancer history (MTC/MEN2), pancreatitis history, gallbladder disease risk, and review other GLP-1 precautions.
  • Plan monitoring: Clinicians will typically pair lifestyle therapy with Wegovy and follow liver lab tests, weight, and non-invasive tests (NITs) as adjuncts between biopsies. In the trial, researchers used both histology and NITs.

Wegovy vs. Rezdiffra for MASH

Rezdiffra (resmetirom) was the first FDA-approved MASH drug in 2024. It’s a thyroid hormone receptor-beta (THR-beta) agonist, and helps the liver burn more fat and make less of it, which reduces the fat buildup that drives MASH.

Currently, there are no head-to-head studies directly comparing Wegovy and Rezdiffra.

Looking at their separate trials, the ESSENCE trial (72 weeks) showed that Wegovy led to 63% resolution of MASH and 37% improvement in fibrosis. In contrast, the MAESTRO-NASH trial (52 weeks) with Rezdiffra reported 26-30% resolution and 24-26% fibrosis improvement.

These results give us useful insights, but don’t allow a direct comparison. More studies are expected in the near future that will evaluate the two drugs against each other.

Should You Ask Your Doctor About Wegovy for MASH?

If you’ve been diagnosed with MASH and liver fibrosis (F2-F3), Wegovy may now be an option to slow progression and protect your liver. Talk with your doctor about whether it’s right for you, what side effects to consider, and how your insurance may handle coverage.

Related Articles

Frequently Asked Questions

No. Wegovy is approved for obesity in adolescents (12 and older) but not specifically for MASH in children.

Yes. In some people, lifestyle changes like losing weight, eating healthier, and exercising can improve or even reverse liver fat and inflammation. However, not everyone can achieve or sustain the weight loss needed, which is why medications like Wegovy are important new options.

No. MASLD (fatty liver with metabolic dysfunction) doesn’t always turn into MASH. Many people stay in the “fatty liver only” stage. Progression depends on factors such as obesity, insulin resistance, genetics, and other health conditions.

The gold standard is a liver biopsy, but non-invasive tools are becoming more common. These include blood tests that estimate fibrosis, imaging techniques like FibroScan, and MRI methods that measure fat and stiffness in the liver.

Yes. Wegovy is most effective when combined with diet and exercise. Lifestyle changes remain the foundation of treatment because they help reduce weight, improve metabolic health, and support long-term liver protection.

In clinical trials, meaningful changes in liver fat and inflammation were seen within the first year. At around 72 weeks (about 1.5 years), patients on Wegovy showed much higher rates of MASH resolution compared to placebo. Improvements may begin earlier, but the biggest benefits appear after sustained treatment.

Most insurers and clinical guidelines still rely on biopsy-confirmed F2-F3 fibrosis to approve treatment. However, non-invasive tests (like FibroScan or blood-based fibrosis scores) may also be accepted depending on the health plan.

We don’t know yet. Because MASH is now a leading cause of liver cancer, researchers hope that improving inflammation and fibrosis with Wegovy will reduce cancer risk. The long-term ESSENCE trial is tracking these outcomes.

Wegovy doesn’t have many direct drug-drug interactions. However, because it slows stomach emptying, it may affect how quickly some oral medications are absorbed. Review all your prescriptions with your doctor before starting.

Sources

Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., Yong, J. N., Zeng, R. W., Chew, N. W. S., Nah, B., Kulkarni, A., Siddiqui, M. S., Dan, Y. Y., Wong, V. W., Sanyal, A. J., . . . Ng, C. H. (2022). Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. ?the ?Lancet. Gastroenterology & Hepatology, 8(1), 20–30. https://doi.org/10.1016/s2468-1253(22)00317-x

Younossi, Z. M., Mangla, K. K., Chandramouli, A. S., & Lazarus, J. V. (2024). Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH. Hepatology Communications, 8(8). https://doi.org/10.1097/hc9.0000000000000488

Danpanichkul, P., Suparan, K., Kaeosri, C., Jatupornpakdee, P., Attia, A. M., Suenghataiphorn, T., Thongpiya, J., Sukphutanan, B., Huang, D. Q., Noureddin, M., Singal, A. G., Wijarnpreecha, K., & Yang, J. D. (2024). Global Trend of MASH-associated Liver Cancer A Systematic Analysis from the Global Burden of Disease 2021. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.10.026

Huang, D. Q., Singal, A. G., Kono, Y., Tan, D. J., El-Serag, H. B., & Loomba, R. (2022). Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism, 34(7), 969-977.e2. https://doi.org/10.1016/j.cmet.2022.05.003

Ezhilarasan, D. (2025). Mechanism of semaglutide in MASLD treatment: Where is the master key? Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.17037

Folestad, E., & Falkevall, A. (2024). “Regulation of adipose-derived fatty acid fluxes to the liver”-Impact on Metabolic dysfunction-associated steatotic liver disease. Current Opinion in Endocrine and Metabolic Research, 100559. https://doi.org/10.1016/j.coemr.2024.100559

Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024). Glucagon-Like peptide-1: new regulator in lipid metabolism. Diabetes & Metabolism Journal, 48(3), 354–372. https://doi.org/10.4093/dmj.2023.0277

Patel, S., & Niazi, S. K. (2025). Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025). Pharmaceutics, 17(8), 1036. https://doi.org/10.3390/pharmaceutics17081036

Hu, Q., Zhang, L., Tao, Y., Xie, S., Wang, A., Luo, C., Yang, R., Shen, Z., He, B., Fang, Y., & Chen, P. (2024). Semaglutide ameliorates hepatocyte steatosis in a cell Co-Culture system by downregulating the IRE1?-XBP1-C/EBP? signaling pathway in macrophages. Pharmacology, 1–10. https://doi.org/10.1159/000540654

Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V. (2025). Phase 3 trial of semaglutide in Metabolic Dysfunction–Associated steatohepatitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2413258

Kffjuliettec. (2025, August 9). A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity. KFF. https://www.kff.org/medicare/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/

Myshko, D. (2025, May 1). CVS Caremark to place Wegovy as preferred GLP-1 for weight loss. Managed Healthcare Executive. https://www.managedhealthcareexecutive.com/view/cvs-caremark-to-place-wegovy-as-preferred-glp-1-for-weight-loss

Office of the Commissioner. (2024, March 14). FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. U.S. Food And Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., . . . Ratziu, V. (2024). A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine, 390(6), 497–509. https://doi.org/10.1056/nejmoa2309000